alosetron has been researched along with Colonic Diseases, Functional in 80 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Colonic Diseases, Functional: Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and tolerability of alosetron in women with diarrhea-predominant irritable bowel syndrome (IBS) have been established in double-blind, placebo-controlled trials." | 9.10 | Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. ( Bagby, B; Bobbitt, W; Carter, E; Dahdul, A; DeCastro, E; Decker, C; DeGarmo, RG; Gringeri, L; Jhingran, P; Johanson, J; Levinson, L; Markowitz, M; Mula, G; Olden, K; Poleynard, G; Stoltz, RR; Truesdale, R; Young, D, 2002) |
| "The aim of this study was to assess the impact of alosetron, a treatment recently approved in the United States for irritable bowel syndrome in diarrhea-predominant female patients, on health-related quality of life." | 9.09 | Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. ( Hahn, B; Kong, S; Lacey, L; Mangel, AW; McSorley, D; Northcutt, AR; Watson, ME, 2001) |
| "Alosetron hydrochloride, 1 mg twice daily for 12 weeks, is effective in relieving pain and some bowel-related symptoms in diarrhea-predominant female patients with IBS." | 9.09 | A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. ( Camilleri, M; Chey, WY; Dukes, GE; Heath, A; Mangel, AM; Mayer, EA; McSorley, D; Northcutt, AR, 2001) |
| "The aim of this study was to establish a pathophysiologic model of irritable bowel syndrome, and then to evaluate the pharmaceutical efficacy of ramosetron, a potent serotonin 3 (5-HT(3)) receptor antagonist, and other anti-irritable bowel syndrome agents in this model." | 7.74 | Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A, 2007) |
| "Alosetron-treated patients showed improvements in bowel functions compared to placebo-treated patients." | 6.70 | Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. ( Bagby, B; Carter, E; Decker, C; Gordon, S; Jhingran, P; Lembo, T; Wright, RA, 2001) |
| "Alosetron is a potent and selective serotonin antagonist that recently became the first Food and Drug Administration-approved agent for diarrhea-predominant IBS." | 5.31 | Ischemic colitis during treatment with alosetron. ( Fisher, RS; Friedel, D; Thomas, R, 2001) |
| "The efficacy and tolerability of alosetron in women with diarrhea-predominant irritable bowel syndrome (IBS) have been established in double-blind, placebo-controlled trials." | 5.10 | Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. ( Bagby, B; Bobbitt, W; Carter, E; Dahdul, A; DeCastro, E; Decker, C; DeGarmo, RG; Gringeri, L; Jhingran, P; Johanson, J; Levinson, L; Markowitz, M; Mula, G; Olden, K; Poleynard, G; Stoltz, RR; Truesdale, R; Young, D, 2002) |
| "In female irritable bowel syndrome patients with predominant diarrhoea or alternating constipation and diarrhoea, alosetron is effective in treatment of abdominal pain and discomfort and bowel-related symptoms." | 5.09 | Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. ( Camilleri, M; Drossman, DA; Dukes, GE; Heath, A; Kong, S; Mangel, AW; Mayer, EA; McSorley, D; Northcutt, AR, 1999) |
| "The aim of this study was to assess the impact of alosetron, a treatment recently approved in the United States for irritable bowel syndrome in diarrhea-predominant female patients, on health-related quality of life." | 5.09 | Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. ( Hahn, B; Kong, S; Lacey, L; Mangel, AW; McSorley, D; Northcutt, AR; Watson, ME, 2001) |
| "Alosetron hydrochloride, 1 mg twice daily for 12 weeks, is effective in relieving pain and some bowel-related symptoms in diarrhea-predominant female patients with IBS." | 5.09 | A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. ( Camilleri, M; Chey, WY; Dukes, GE; Heath, A; Mangel, AM; Mayer, EA; McSorley, D; Northcutt, AR, 2001) |
| ", 2D6 and 2C19), and the effects of genetic polymorphisms in the promoter of the serotonin transporter protein, which influence the response to alosetron in patients with diarrhea-predominant irritable bowel syndrome." | 4.82 | Pharmacogenomics and functional gastrointestinal disorders. ( Camilleri, M, 2005) |
| "The aim of this study was to establish a pathophysiologic model of irritable bowel syndrome, and then to evaluate the pharmaceutical efficacy of ramosetron, a potent serotonin 3 (5-HT(3)) receptor antagonist, and other anti-irritable bowel syndrome agents in this model." | 3.74 | Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats. ( Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A, 2007) |
| "A 5-HT3 antagonist, alosetron, significantly retards small intestinal and colonic transit in diarrhea-predominant IBS patients, with significantly greater female to male responsiveness." | 3.71 | Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. ( Burton, D; Camilleri, M; McKinzie, S; Pardi, DS; Thomforde, GM; Viramontes, BE, 2001) |
| "Alosetron (Lotronex) is a new therapeutic agent for irritable bowel syndrome (IBS) in women with diarrhea-predominant IBS." | 2.70 | Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. ( Chey, WY; Dukes, GE; Harding, J; Heath, AT; Hunt, CM; McSorley, DJ; Washington, MK; Wolfe, SG, 2001) |
| "Fluoxetine is an antidepressant that is administered as a racemic mixture of equipotent R- and S-enantiomers." | 2.70 | Effect of alosetron on the pharmacokinetics of fluoxetine. ( D'Souza, DL; Dimmitt, DC; Koch, KM; Nezamis, J; Robbins, DK; Simms, L, 2001) |
| "Alosetron-treated patients showed improvements in bowel functions compared to placebo-treated patients." | 2.70 | Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. ( Bagby, B; Carter, E; Decker, C; Gordon, S; Jhingran, P; Lembo, T; Wright, RA, 2001) |
| "Alosetron appeared to increase the overall periprandial frequency in the sigmoid colon (P=0." | 2.70 | Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers. ( Clemens, CH; Fabri, M; Samsom, M; Smout, AJ; Van Berge Henegouwen, GP, 2002) |
| "Alosetron was well tolerated and clinically effective in alleviating pain and bowel-related symptoms in this population of women with IBS." | 2.69 | Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. ( Camilleri, M; Dukes, GE; Kong, S; Mangel, AW; McSorley, D; Northcutt, AR, 2000) |
| "Alosetron is a potent and selective 5-HT3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non-constipated irritable bowel syndrome." | 2.69 | Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. ( Foster, JM; Houghton, LA; Whorwell, PJ, 2000) |
| "Alosetron is a potent and highly selective serotonin 5-HT3 receptor antagonist which has been evaluated for the management of irritable bowel syndrome (IBS)." | 2.41 | Alosetron. ( Balfour, JA; Goa, KL; Perry, CM, 2000) |
| "Alosetron is a highly selective, potent 5-HT3 receptor antagonist which is well absorbed with a long pharmacodynamic half-life." | 2.40 | Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome. ( Bountra, C; Clayton, N; Humphrey, PP; Kozlowski, K, 1999) |
| "Alosetron was shown to dose-dependently inhibit the 5-HT-induced skin flare response, increase colonic transit time and increase basal jejunal water and electrolyte absorption, in healthy volunteers." | 2.40 | Review article: clinical pharmacology of alosetron. ( Gunput, MD, 1999) |
| "Alosetron has been shown to produce statistically significant improvements in abdominal pain, stool consistency, stool frequency and urgency in female IBS patients." | 2.40 | Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. ( Mangel, AW; Northcutt, AR, 1999) |
| "Alosetron is a potent and selective serotonin antagonist that recently became the first Food and Drug Administration-approved agent for diarrhea-predominant IBS." | 1.31 | Ischemic colitis during treatment with alosetron. ( Fisher, RS; Friedel, D; Thomas, R, 2001) |
| "Alosetron (Lotronex) is a serotonin subtype 3 (5-HT3) receptor antagonist that alleviates symptoms of irritable bowel syndrome (IBS) in female patients." | 1.31 | Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro. ( Bush, TG; Sanders, KM; Smith, TK; Spencer, NJ; Watters, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (11.25) | 18.2507 |
| 2000's | 71 (88.75) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Young, D | 2 |
| Mayer, EA | 4 |
| Berman, S | 1 |
| Derbyshire, SW | 2 |
| Suyenobu, B | 2 |
| Chang, L | 2 |
| Fitzgerald, L | 2 |
| Mandelkern, M | 2 |
| Hamm, L | 2 |
| Vogt, B | 2 |
| Naliboff, BD | 2 |
| Camilleri, M | 10 |
| Atanasova, E | 1 |
| Carlson, PJ | 1 |
| Ahmad, U | 1 |
| Kim, HJ | 1 |
| Viramontes, BE | 2 |
| McKinzie, S | 2 |
| Urrutia, R | 1 |
| Longstreth, GF | 1 |
| Drossman, DA | 2 |
| Lièvre, M | 1 |
| Moynihan, R | 2 |
| Giaquinta, D | 1 |
| Berman, SM | 1 |
| Stains, J | 1 |
| Horwitz, BJ | 1 |
| Brandt, LJ | 1 |
| Bjorkman, D | 1 |
| Fennerty, MB | 1 |
| Locke, GR | 1 |
| Olden, K | 2 |
| Peterson, W | 1 |
| Quigley, E | 1 |
| Schoenfeld, P | 1 |
| Schuster, M | 1 |
| Talley, N | 1 |
| DeGarmo, RG | 1 |
| Jhingran, P | 2 |
| Bagby, B | 2 |
| Decker, C | 2 |
| Markowitz, M | 1 |
| Carter, E | 2 |
| Bobbitt, W | 1 |
| Dahdul, A | 1 |
| DeCastro, E | 1 |
| Gringeri, L | 1 |
| Johanson, J | 1 |
| Levinson, L | 1 |
| Mula, G | 1 |
| Poleynard, G | 1 |
| Stoltz, RR | 1 |
| Truesdale, R | 1 |
| Palmer, JB | 1 |
| Palmer, RH | 1 |
| Simrén, M | 1 |
| Simms, L | 2 |
| D'Souza, D | 1 |
| Abrahamsson, H | 1 |
| Björnsson, ES | 1 |
| Shen, B | 2 |
| Soffer, EE | 1 |
| Cremonini, F | 1 |
| Delgado-Aros, S | 1 |
| Ladabaum, U | 1 |
| Chey, WD | 1 |
| Olden, KW | 1 |
| Hyman, PE | 1 |
| Garvey, TQ | 1 |
| Avigan, M | 1 |
| Justice, R | 1 |
| Mackey, AC | 1 |
| Nair, N | 1 |
| Funatsu, T | 1 |
| Takeuchi, A | 1 |
| Hirata, T | 1 |
| Keto, Y | 1 |
| Akuzawa, S | 1 |
| Sasamata, M | 1 |
| Delvaux, M | 2 |
| Louvel, D | 1 |
| Mamet, JP | 1 |
| Campos-Oriola, R | 1 |
| Frexinos, J | 2 |
| Gershon, MD | 1 |
| Humphrey, PP | 1 |
| Bountra, C | 1 |
| Clayton, N | 1 |
| Kozlowski, K | 1 |
| Pappas, TN | 1 |
| Mangel, AW | 5 |
| Lawson, C | 1 |
| Gunput, MD | 1 |
| Northcutt, AR | 5 |
| Heath, A | 3 |
| Dukes, GE | 4 |
| McSorley, D | 4 |
| Kong, S | 3 |
| Jones, RH | 1 |
| Holtmann, G | 1 |
| Rodrigo, L | 1 |
| Ehsanullah, RS | 1 |
| Crompton, PM | 1 |
| Jacques, LA | 2 |
| Mills, JG | 2 |
| Bardhan, KD | 1 |
| Bodemar, G | 1 |
| Geldof, H | 1 |
| Schütz, E | 1 |
| Lembo, T | 2 |
| Miller, JL | 2 |
| Balfour, JA | 1 |
| Goa, KL | 1 |
| Perry, CM | 1 |
| Houghton, LA | 1 |
| Foster, JM | 1 |
| Whorwell, PJ | 2 |
| Thumshirn, M | 1 |
| Coulie, B | 2 |
| Zinsmeister, AR | 1 |
| Burton, DD | 1 |
| Van Dyke, C | 1 |
| Kupecz, D | 1 |
| McColl, KE | 1 |
| Müller-Lissner, SA | 1 |
| Shapiro, JP | 1 |
| Barbehenn, E | 1 |
| Lurie, P | 1 |
| Wolfe, SM | 1 |
| Friedel, D | 1 |
| Thomas, R | 1 |
| Fisher, RS | 1 |
| Thompson, CA | 1 |
| Charatan, F | 2 |
| Watson, ME | 1 |
| Lacey, L | 1 |
| Hahn, B | 1 |
| Soffer, E | 1 |
| Wolfe, SG | 1 |
| Chey, WY | 2 |
| Washington, MK | 1 |
| Harding, J | 1 |
| Heath, AT | 1 |
| McSorley, DJ | 1 |
| Hunt, CM | 1 |
| D'Souza, DL | 1 |
| Dimmitt, DC | 1 |
| Robbins, DK | 1 |
| Nezamis, J | 1 |
| Koch, KM | 1 |
| Hollerbach, S | 1 |
| Elsenbruch, S | 1 |
| Enck, P | 1 |
| Horton, R | 1 |
| Hyams, JS | 1 |
| Mangel, AM | 1 |
| Bush, TG | 1 |
| Spencer, NJ | 1 |
| Watters, N | 1 |
| Sanders, KM | 1 |
| Smith, TK | 1 |
| Wright, RA | 1 |
| Gordon, S | 1 |
| Pardi, DS | 1 |
| Burton, D | 1 |
| Thomforde, GM | 1 |
| Matsueda, K | 1 |
| Talley, NJ | 1 |
| Blackington, E | 1 |
| Chassany, O | 1 |
| Bergmann, JF | 1 |
| Clemens, CH | 1 |
| Samsom, M | 1 |
| Van Berge Henegouwen, GP | 1 |
| Fabri, M | 1 |
| Smout, AJ | 1 |
| McCarthy, M | 2 |
21 reviews available for alosetron and Colonic Diseases, Functional
| Article | Year |
|---|---|
New developments in the diagnosis and treatment of irritable bowel syndrome.
Topics: Anti-Bacterial Agents; Carbolines; Celiac Disease; Clinical Trials as Topic; Colonic Diseases, Funct | 2002 |
Alosetron: a case study in regulatory capture, or a victory for patients' rights?
Topics: Carbolines; Colonic Diseases, Functional; Drug Approval; Gastrointestinal Agents; Humans; Patient Ri | 2002 |
Systematic review on the management of irritable bowel syndrome in North America.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Behavior Therapy; Carbolines; Cathartics; Colonic | 2002 |
Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Female; Humans; Male; Randomized Controlled Tria | 2003 |
Tegaserod and other serotonergic agents: what is the evidence?
Topics: Carbolines; Colonic Diseases, Functional; Humans; Indoles; Serotonin Antagonists; Serotonin Receptor | 2003 |
Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.
Topics: Antidepressive Agents; Benzofurans; Carbazoles; Carbolines; Colonic Diseases, Functional; Gastrointe | 2003 |
Pharmacogenomics and functional gastrointestinal disorders.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Dyspepsia; Gastrointestinal Agents; Humans; Mode | 2005 |
Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel.
Topics: Animals; Carbolines; Colonic Diseases, Functional; Humans; Intestinal Mucosa; Intestines; Receptors, | 1999 |
Review article: the therapeutic potential of 5-HT3 receptor antagonists in the treatment of irritable bowel syndrome.
Topics: Animals; Carbolines; Colonic Diseases, Functional; Humans; Intestines; Receptors, Serotonin; Seroton | 1999 |
Review article: evaluation of drugs in experimental gut distension models.
Topics: Abdominal Pain; Animals; Carbolines; Colonic Diseases, Functional; Disease Models, Animal; Dogs; Ser | 1999 |
Review article: clinical pharmacology of alosetron.
Topics: Carbolines; Colonic Diseases, Functional; Gastrointestinal Transit; Humans; Hydrogen-Ion Concentrati | 1999 |
Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Topics: Abdominal Pain; Carbolines; Colonic Diseases, Functional; Female; Humans; Male; Randomized Controlle | 1999 |
Alosetron.
Topics: Adult; Animals; Area Under Curve; Biological Availability; Carbolines; Colonic Diseases, Functional; | 2000 |
New therapies for functional bowel diseases.
Topics: Carbolines; Colonic Diseases, Functional; Dyspepsia; Gastrointestinal Agents; Humans; Psychotherapy | 2000 |
The challenge of irritable bowel syndrome: creating an alliance between patient and physician.
Topics: Abdominal Pain; Antidepressive Agents; Antidiarrheals; Carbolines; Cholinergic Antagonists; Colonic | 2001 |
Novel medications for the irritable bowel syndrome: motility and sensation.
Topics: Abdominal Pain; Animals; Carbolines; Colonic Diseases, Functional; Constipation; Female; Gastrointes | 2001 |
[Irritable bowel syndrome as an interdisciplinary clinical challenge. Current views on its pathophysiology, diagnosis and treatment].
Topics: Adult; Carbolines; Clinical Trials as Topic; Colonic Diseases, Functional; Diagnosis, Differential; | 2001 |
[Irritable bowel syndrome: diagnostic criteria and recent advancement of its pharmacological management].
Topics: Acrylic Resins; Carbolines; Colonic Diseases, Functional; Gastrointestinal Agents; Humans; Serotonin | 2001 |
Serotoninergic neuroenteric modulators.
Topics: Benzofurans; Carbolines; Clinical Trials as Topic; Colonic Diseases, Functional; Female; Humans; Ind | 2001 |
Irritable bowel syndrome: an update on treatment options.
Topics: Adaptation, Psychological; Antidepressive Agents; Antidiarrheals; Carbolines; Colonic Diseases, Func | 2000 |
[Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives].
Topics: Abdominal Pain; Animals; Benzyl Compounds; Carbolines; Central Nervous System; Colitis, Ulcerative; | 2001 |
19 trials available for alosetron and Colonic Diseases, Functional
| Article | Year |
|---|---|
The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Topics: Adult; Brain; Brain Chemistry; Carbolines; Cerebrovascular Circulation; Colonic Diseases, Functional | 2002 |
Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
Topics: Adult; Brain; Brain Chemistry; Carbolines; Catheterization; Colon; Colonic Diseases, Functional; Fem | 2002 |
Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Carbolines; Colonic Diseases, Functional; Diarrhea; Female; Gastrointestinal Agents; Humans; | 2002 |
Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.
Topics: Adult; Carbolines; Catheterization; Colonic Diseases, Functional; Cross-Over Studies; Diarrhea; Doub | 2003 |
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
Topics: Adult; Carbolines; Colon; Colonic Diseases, Functional; Compliance; Double-Blind Method; Female; Hum | 1998 |
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
Topics: Abdominal Pain; Adult; Canada; Carbolines; Colonic Diseases, Functional; Diarrhea; Dose-Response Rel | 1999 |
Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Topics: Adolescent; Adult; Carbolines; Colonic Diseases, Functional; Double-Blind Method; Female; Humans; Pa | 1999 |
A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
Topics: Adolescent; Adult; Aged; Carbolines; Colonic Diseases, Functional; Double-Blind Method; Female; Huma | 2000 |
Neurotransmitter antagonism in management of irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Humans; Serotonin; Serotonin Antagonists | 2000 |
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Topics: Administration, Oral; Adult; Carbolines; Colonic Diseases, Functional; Drug Administration Schedule; | 2000 |
Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Topics: Adult; Carbolines; Colon; Colonic Diseases, Functional; Cross-Over Studies; Double-Blind Method; Fem | 2000 |
Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Topics: Adult; Aged; Carbolines; Colonic Diseases, Functional; Double-Blind Method; Female; Gastrointestinal | 2000 |
[New therapeutic approaches in irritable bowel syndrome].
Topics: Carbolines; Colonic Diseases, Functional; Double-Blind Method; Female; Humans; Serotonin Antagonists | 2000 |
Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Double-Blind Method; Female; Humans; Middle Aged | 2001 |
Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
Topics: Carbolines; Colonic Diseases, Functional; Constipation; Double-Blind Method; Female; Humans; Male; S | 2001 |
Effect of alosetron on the pharmacokinetics of fluoxetine.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Biological Availability; Carb | 2001 |
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Topics: Administration, Oral; Adult; Aged; Carbolines; Colonic Diseases, Functional; Diarrhea; Drug Administ | 2001 |
Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Diarrhea; Female; Humans; Middle Aged; Serotonin Antagonis | 2001 |
Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Topics: Adult; Carbolines; Colon; Colonic Diseases, Functional; Cross-Over Studies; Defecation; Double-Blind | 2002 |
40 other studies available for alosetron and Colonic Diseases, Functional
| Article | Year |
|---|---|
Alosetron to return to market.
Topics: Carbolines; Colonic Diseases, Functional; Drug Approval; Drug Labeling; Drug Prescriptions; Gastroin | 2002 |
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Carbolines; Carrier Proteins; Colon; Colonic Diseases, Functional; Diarrhea; Female; Humans; | 2002 |
Alosetron (lotronex) revisited.
Topics: Carbolines; Colonic Diseases, Functional; Constipation; Cost-Benefit Analysis; Female; Humans; Produ | 2002 |
Alosetron for irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Female; Gastrointestinal Agents; Humans; Male | 2002 |
FDA advisers warn of more deaths if drug is relaunched.
Topics: Carbolines; Colonic Diseases, Functional; Drug Approval; Gastrointestinal Agents; Humans; United Sta | 2002 |
Contemporary thoughts on the treatment of irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Drug Approval; Gastrointestinal Agents; Humans; United Sta | 2002 |
FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
Topics: Carbolines; Colonic Diseases, Functional; Diagnosis, Differential; Drug Approval; Female; Gastrointe | 2002 |
Evidence-based position statement on the management of irritable bowel syndrome in North America.
Topics: Antidepressive Agents, Tricyclic; Antidiarrheals; Behavior Therapy; Carbolines; Cathartics; Colonic | 2002 |
Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.
Topics: Carbolines; Colonic Diseases, Functional; Drug and Narcotic Control; Drug Industry; Gastrointestinal | 2003 |
Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
Topics: Carbolines; Colonic Diseases, Functional; Gastrointestinal Agents; Humans; Risk Factors | 2003 |
Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?
Topics: Carbolines; Colonic Diseases, Functional; Contraindications; Diarrhea; Gastrointestinal Agents; Huma | 2003 |
Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications.
Topics: Carbolines; Colonic Diseases, Functional; Cost-Benefit Analysis; Diarrhea; Female; Gastrointestinal | 2003 |
Return of alosetron.
Topics: Adolescent; Adult; Carbolines; Colonic Diseases, Functional; Drug Approval; Female; Gastrointestinal | 2002 |
Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
Topics: Adverse Drug Reaction Reporting Systems; Carbolines; Clinical Trials as Topic; Colitis, Ischemic; Co | 2003 |
Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
Topics: Animals; Behavior, Animal; Benzimidazoles; Carbazoles; Carbolines; Colon; Colonic Diseases, Function | 2007 |
Irritable bowel syndrome and the role of 5-HT. Proceedings of a roundtable meeting. New Orleans, Louisiana, USA. May 1998.
Topics: Animals; Carbolines; Colonic Diseases, Functional; Humans; Serotonin; Serotonin Antagonists | 1999 |
New drugs to treat irritable bowel syndrome being tested.
Topics: Benzofurans; Carbolines; Colonic Diseases, Functional; Female; Gastrointestinal Agents; Guanidines; | 2000 |
Alosetron approved for treatment of irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Drug Approval; Female; Humans; Serotonin Antagonists; Unit | 2000 |
Irritable bowel syndrome. New treatment drug on the market.
Topics: Carbolines; Colitis, Ischemic; Colonic Diseases, Functional; Constipation; Humans; Serotonin Antagon | 2000 |
Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Constipation; Dose-Response Relationship, Drug; Fees, Phar | 2000 |
Alosetron: a new therapy for irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Humans; Practice Guidelines as Topic; Serotonin Antagonist | 2000 |
Alosetron in irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Constipation; Female; Humans; Quality of Life; Randomized | 2000 |
Linezolid, Alosetron, Levetiracetam.
Topics: Acetamides; Adult; Anti-Infective Agents; Anticonvulsants; Carbolines; Colonic Diseases, Functional; | 2000 |
[Soon one "female distress" less. Irritable bowel syndrome responds to serotonin blockers].
Topics: Carbolines; Colonic Diseases, Functional; Female; Gastrointestinal Motility; Humans; Serotonin Antag | 2000 |
FDA draws patients into alosetron risk management.
Topics: Carbolines; Colitis, Ischemic; Colonic Diseases, Functional; Constipation; Contraindications; Drug L | 2000 |
A pill turned bitter. How a quest for a blockbuster drug went fatally wrong.
Topics: Carbolines; Colonic Diseases, Functional; Drug Approval; Fatal Outcome; Female; Gastrointestinal Age | 2000 |
Alosetron for irritable bowel syndrome.
Topics: Carbolines; Colonic Diseases, Functional; Female; Humans; Serotonin Antagonists | 2000 |
Ischemic colitis during treatment with alosetron.
Topics: Carbolines; Colitis; Colonic Diseases, Functional; Colonoscopy; Humans; Ischemia; Male; Middle Aged; | 2001 |
Lotronex withdrawn from market.
Topics: Carbolines; Colonic Diseases, Functional; Drug Approval; Female; Gastrointestinal Agents; Humans | 2001 |
Alosetron withdrawn from market.
Topics: Carbolines; Colonic Diseases, Functional; Drug and Narcotic Control; Female; Humans; Serotonin Antag | 2001 |
Drug for irritable bowel syndrome taken off the market.
Topics: Carbolines; Colonic Diseases, Functional; Drug and Narcotic Control; Female; Humans; Serotonin Antag | 2000 |
Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.
Topics: Adult; Aged; Carbolines; Colonic Diseases, Functional; Female; Gastrointestinal Agents; Humans; Midd | 2001 |
Lotronex and the FDA: a fatal erosion of integrity.
Topics: Carbolines; Colitis, Ischemic; Colonic Diseases, Functional; Drug and Narcotic Control; Drug Approva | 2001 |
So what happened to alosetron?
Topics: Carbolines; Colonic Diseases, Functional; Gastrointestinal Agents; Humans; Safety; Serotonin Antagon | 2001 |
Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
Topics: Animals; Carbolines; Colon; Colonic Diseases, Functional; Disease Models, Animal; Dose-Response Rela | 2001 |
Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.
Topics: Adult; Carbolines; Colon; Colonic Diseases, Functional; Diarrhea; Female; Gastrointestinal Transit; | 2001 |
[Functional intestinal disorders and quality of life].
Topics: Acupuncture Therapy; Benzyl Compounds; Carbolines; Colonic Diseases, Functional; Data Interpretation | 2001 |
FDA recommends bringing controversial IBS drug back.
Topics: Carbolines; Colonic Diseases, Functional; Drug Approval; Humans; Serotonin Antagonists; United State | 2002 |
FDA advisory panels recommend Lotronex be put back on market.
Topics: Advisory Committees; Carbolines; Colonic Diseases, Functional; Drug Approval; Gastrointestinal Agent | 2002 |
FDA allows controversial bowel drug back on to market.
Topics: Carbolines; Colonic Diseases, Functional; Female; Humans; Male; Serotonin Antagonists; United States | 2002 |